ScholarIQanswers from OpenAlex & ORCID
Philippe Aftimos
ResearcherPublications, citations & collaboration network
Philippe Aftimos is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Philippe Aftimos have?
ScholarIQindexed works
Philippe Aftimos has 329 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Philippe Aftimos have?
ScholarIQcitation count
Philippe Aftimos has 8,166 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Philippe Aftimos?
ScholarIQh-index
Philippe Aftimos has an h-index of 36 in OpenAlex.
What is the i10-index of Philippe Aftimos?
ScholarIQi10-index
Philippe Aftimos has an i10-index of 108 in OpenAlex.
What is the ORCID of Philippe Aftimos?
ScholarIQorcid
The ORCID for Philippe Aftimos is on the source record.
What is the OpenAlex record for Philippe Aftimos?
ScholarIQopenalex
The OpenAlex for Philippe Aftimos is on the source record.
What are the most-cited papers on Philippe Aftimos?
ScholarIQmost cited works
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie‐Ange Mouret‐Reynier, Joohyuk Sohn, Donatienne Taylor, Kathleen Harnden, Hung T. Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, José Á. García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortés, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji, Carla M.L. van Herpen, Cristina Saura, Fiona Thistlethwaite, Simon Lord, Víctor Moreno, Iain R. Macpherson, Valentina Boni, Christian Rolfo, Elisabeth G.E. de Vries, Sylvie Rottey, Jill J.J. Geenen, Ferry A.L.M. Eskens, Marta Gil-Martín, Ellen C.M. Mommers, N.P. Koper, Philippe Aftimos
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Yacine Barèche, David Venet, Michail Ignatiadis, Philippe Aftimos, Martine Piccart, Françoise Rothé, Christos Sotiriou
Delivering precision oncology to patients with cancer
Joaquı́n Mateo, Lotte Steuten, Philippe Aftimos, Fabrice André, D. M. Davies, Elena Garralda, Jan Geißler, Don Husereau, Iciar Martinez-Lopez, Nicola Normanno, Jorge S. Reis‐Filho, Stephen Stefani, David M. Thomas, C. Benedikt Westphalen, Emile E. Voest